Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase

US7595327B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Jeremy Levin · New City, US
• Zhong Li · Lo Wu, CN
• George Diamantidis · Dover, US
• Frank Eldridge Lovering · Acton, US
• Weiheng Wang · Bedford, US
• Jeffrey Scott Condon · Cambridge, US
• Yang-I Lin · Nanuet, US
• Jerauld S. Skotnicki · Allentown, US
• Kaapjoo Park · Congers, US

Key dates

• Filing date: Mar 16, 2006
• Grant date: Sep 29, 2009
• Expiry date: Dec 8, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention provides compounds of Formula I, having the structure:that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.